Agent for preventing and/or treating multiple organ failure

Details Agent for preventing and/or treating multiple organ failure Agent for preventing and/or treating multiple organ failure

2007-12-11

2007-12-11

Weber, Jon (Department: 1654)

Drug, bio-affecting and body treating compositions

Lymphokine

C514S008100, C514S021800, C514S970000, C530S395000, C530S399000

Reexamination Certificate

active

10317011

ABSTRACT:
The present invention provides methods of preventing and/or treating multiple organ failure comprising the step of administering a therapeutically effective amount of agent comprising tumor cytotoxic factor-II (TCF-II) or hepatocyte growth factor (HGF). Methods of the present invention will be useful for preventing and/or treating the development of multiple organ failure resulting from burn, disseminated intravascular coagulation (DIC), circulatory failure, hemorrhagic shock, infectious disease, acute pancreatitis, ischemic disorder, hepatorenal syndrome, gastrointestinal hemorrhage, nutritional metabolic failure, terminal cancer, acquired immunodeficiency syndrome (AIDS), deterioration of systemic conditions due to radiation affection, and cachexia.

REFERENCES:
patent: 3904753 (1975-09-01), Sonenberg et al.
patent: 4076701 (1978-02-01), Burton et al.
patent: 4481137 (1984-11-01), Ohnishi et al.
patent: 4490549 (1984-12-01), Johnson
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4767701 (1988-08-01), Burton et al.
patent: 4777241 (1988-10-01), Irikura et al.
patent: 4822605 (1989-04-01), Powell
patent: 4870163 (1989-09-01), Rubin et al.
patent: 5091511 (1992-02-01), Sone et al.
patent: 5328836 (1994-07-01), Shima et al.
patent: 5362716 (1994-11-01), Kmiecik et al.
patent: 5432267 (1995-07-01), Kusama et al.
patent: 5510327 (1996-04-01), Hayasaka et al.
patent: 5547856 (1996-08-01), Godowski et al.
patent: 5587359 (1996-12-01), Higashio et al.
patent: 5589451 (1996-12-01), Wilson
patent: 5606029 (1997-02-01), Degen
patent: 5648233 (1997-07-01), Yamaguchi et al.
patent: 5648273 (1997-07-01), Bottaro et al.
patent: 5658742 (1997-08-01), Higashio et al.
patent: 5703047 (1997-12-01), Wilson
patent: 5703048 (1997-12-01), Roos et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5714461 (1998-02-01), Masunaga et al.
patent: 5760177 (1998-06-01), Iwanaga et al.
patent: 5776464 (1998-07-01), Nakamura
patent: 5821223 (1998-10-01), Rubin et al.
patent: 5998370 (1999-12-01), Arai
patent: 6306827 (2001-10-01), Kinosaki et al.
patent: 6333309 (2001-12-01), Higashio
patent: 2002/0041863 (2002-04-01), Kojiro et al.
patent: 2003/0082134 (2003-05-01), Kojiro et al.
patent: 2003/0236191 (2003-12-01), Kijiro et al.
patent: 2218864 (1996-10-01), None
patent: 2100720 (2003-03-01), None
patent: 2116192 (2005-05-01), None
patent: 0 322 084 (1989-06-01), None
patent: 0 456 188 (1991-11-01), None
patent: 0 462 549 (1991-12-01), None
patent: 0 498 680 (1992-08-01), None
patent: 0 519 728 (1992-12-01), None
patent: 0 587 311 (1994-03-01), None
patent: 0 588 477 (1994-03-01), None
patent: 0588477 (1994-03-01), None
patent: 0 604 184 (1994-06-01), None
patent: 0 604 185 (1994-06-01), None
patent: 0 462 277 (1995-06-01), None
patent: 0 724 884 (1996-08-01), None
patent: 0 757 994 (1997-02-01), None
patent: 0 821 969 (1998-02-01), None
patent: 0 461 560 (1998-11-01), None
patent: 0 539 590 (1999-03-01), None
patent: 0 914 829 (1999-05-01), None
patent: 0 925 791 (1999-06-01), None
patent: 0 950 416 (1999-10-01), None
patent: 0 982 037 (2000-03-01), None
patent: 0 612 530 (2000-11-01), None
patent: 0 653 211 (2001-10-01), None
patent: 0 672 685 (2002-08-01), None
patent: 0 891 778 (2004-06-01), None
patent: 6-56692 (1989-03-01), None
patent: 10-68400 (1989-03-01), None
patent: 5244976 (1993-09-01), None
patent: 6-40935 (1994-02-01), None
patent: 6-40938 (1994-02-01), None
patent: 6040934 (1994-02-01), None
patent: 6116299 (1994-04-01), None
patent: 8176007 (1996-07-01), None
patent: 6340546 (1996-08-01), None
patent: 8231418 (1996-09-01), None
patent: 10029951 (1998-02-01), None
patent: 10194986 (1998-07-01), None
patent: 10273446 (1998-10-01), None
patent: WO90/10651 (1990-09-01), None
patent: WO91/03254 (1991-03-01), None
patent: WO93/08821 (1993-05-01), None
patent: WO93/13066 (1993-07-01), None
patent: WO94/14845 (1994-07-01), None
patent: WO96/20004 (1996-07-01), None
patent: WO96/20214 (1996-07-01), None
patent: WO96/28423 (1996-09-01), None
patent: WO96/32960 (1996-10-01), None
patent: WO98/40096 (1998-09-01), None
patent: WO98/41230 (1998-09-01), None
patent: WO98/43665 (1998-10-01), None
patent: WO99/47155 (1999-09-01), None
Cross et al., Infection and Immunity, vol. 61, pp. 2741-2747, 1993.
Fink et al., Journal of Surgical Research, vol. 49, pp. 186-196, 1990.
Roger C. Bone, Annals of Internal Medicine, vol. 115, No. 6, pp. 457-469, 1991.
Glauser et al., The Lancet, vol. 338, pp. 732-736, 1991.
Richman et al. Peritubular Capillaries A Major Target Site of Endotoxin-Induced Injury in the Primate Kidney. 1980, Laboratory Investigation, vol. 43, No. 4, pp. 327-332.
Igawa et al. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury. 1993, Am. J. Physiol., vol. 265, pp. 61-69.
American College of Surgeons Committee on Trauma, (1982), “Early Care of the Injured Patient,” 3rded, Philadelphia, pp. 24-27.
Anscher et al., (1994), “Role of Transforming Growth Factor-β And Hepatocyte Growth Factor in Late Normal Tissue Effects of Radiation,”Radiat. Oncol. Invest.1(6):305-13.
Argiles et al, (1999), “The Role of Cytokines in Cancer Cachexia,”Med. Res. Rev., 19 (3):223-48.
Ashorn, et al., (1990), “An Inhibitor of the Protease Blocks Maturation of Human and Simian Immunodeficiency Viruses and Spread of Infection,”Proc. Natl. Acad. Sci., 87:7472-7476.
Baldwin, et al., (1995), “Structure of HIV-1 Protease with KNI-272, A Tight-Binding Transition-State Analog Containing of Allophenylnorstatine,”Structure, 3(6):81-588.
Bertevello et al., (2001), “Heterogeneous Response of Adipose Tissue to Cancer Cachexia,”Braz. J. Med. Biol. Res., 34(9:1161-1167.
Bossola et al., (2000) “Serum Tumour Necrosis Factor-α Levels in Cancer Patients are Discontinuous and Correlate with Weight Loss,”European Journal of Clinical Investigation, 30:1107-1112.
Cainzos, et al., (1997), “Septic Complications after Billiary Tract Stone Surgery: A Review and Report of the European Prospective Study,”Hepato-Gastroenterology, 44:959-967.
Ceconi, et al., (1998), “Tumor Necrosis Factor in Congestive Heart Failure: A Mechanism of Disease for the New Millennium,”Progress in Cardiovascular Diseases, 41(1)(Suppl. 1):25-30.
Cerra et al., (1987), “Hypermetabolism, organ failure, and metabolic support,”Surgery, vol. 101, 1-14.
Chang, et al., (1998), “The Role of Cytokines in the Catabolic Consequences of Infection and Injury,”Journal of Parenteral and Enteral Nutrition, 22(3):156-166.
Debouck, et al., (1990), “Human Immunodeficiency Virus Protease; A Target for AIDS Therapy,” Drug Development Research, 21:1-17.
Deitch, (1992), “Multiple Organ Failure,”Annals of Surgery, 216(2):117-134.
Deitch et al., (1999), “Prevention of Multiple Organ Failure,”Surgical Clinics of North America, 79(6):1471-1488.
Dube et al., (1988), “Glycosylation at Specific Sites of Erythropoietin Is Essential for Biosyntheis, Secretion, and Biological Function,”Journal of Biological Chemistry, 263(33):17516-17521.
Fahey et al., (1992), “Status of Immune-Based Therapies In HIV Infection and AIDS”Clin., Exp. Immunol., 88:1-5.
Fox, (1994), “No Winners Against AIDS,”Bio/Technology,, 12:128.
Fujiwara et al., (1993), “Stimulation of Liver Growth by Exogenous Human Hepatocyte Growth Factor in Normal and Partially Hepatectomized Rats,”Hepatology, 18(6):1443-1449.
Gohda et al., (1988), “Purification and Partial Characterization of Hepatocyte Growth Factor from Plasma of a Patient with Fulminant Hepatic Failure,”The American Society for Clinical Investigation, 81:414-419.
Goodman & Gilman,The Pharmacological Basis of Therapeutics, 9thEdition, pp. 1654-1659.
Goto, M. et al., “Production of Recombinant Human Erythropoietin in mammalian Cells: Host-Cell Dependency of the Biological Activity of the Cloned Glycoprotein.”Bio/Technology, vol.

Affiliated with

Also associated with

Rating

Agent for preventing and/or treating multiple organ failure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agent for preventing and/or treating multiple organ failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for preventing and/or treating multiple organ failure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3855027